Key TxCell patent to be granted in Japan for its lead product Ovasave®
News Mar 10, 2016
TxCell SA has announced that the Japan Patent Office has indicated that it intends to grant to TxCell a key patent in Japan to cover its lead product Ovasave® and its application to inflammatory bowel disease (IBD). Specifically, the patent covers the administration of a composition that consists of at least one human Type-1 Treg cell population directed against a food antigen from the common human diet.
The equivalent patent has already been granted in the USA (2015), Australia (2015) and Russia (2013). Other corresponding patent applications for Ovasave in IBD are pending in major markets globally. TxCell now owns or controls more than 126 patents that provide coverage for its first platform ASTrIA. These patents are related to the characterisation, production and use of Ag-Tregs for the treatment of chronic autoimmune inflammatory diseases.
"Recent positive developments in both the regulatory field and product approvals means that
Japan has become a key market for cellular immunotherapy,” said Stéphane Boissel, Chief
Executive Officer of TxCell. “The grant of this latest key patent in Japan will help to achieve
TxCell’s ambitious objectives in expanding our global reach.
In addition, TxCell has dedicated years of effort in research and development to establish a robust international intellectual property portfolio. This patent coverage will be critical for our ongoing efforts to make cellular immunotherapies available to the large number of patients with a variety of conditions with unmet medical need.”
Horizon Enters into Partnership with Pirbright Institute to Improve Vaccine YieldsNews
Extends Horizon’s biomanufacturing capabilities into vaccine manufacture. Research supported by a grant from the Canadian International Development Research Centre, funded by the Bill and Melinda Gates foundation.READ MORE
Lonza Opens World’s Largest Dedicated Cell-and-Gene-Therapy Manufacturing Facility in TexasNews
First-of-its-kind, state-of-the-art manufacturing facility with capacity to produce treatment for thousands of patients suffering from rare genetic disorders or life-threatening diseases.READ MORE
IONTAS and IGEM Therapeutics Collaborate to Identify Novel IgE AntibodiesNews
The project will add to IGEM’s pipeline of drugs and expand upon IGEM-F, an IgE targeting ovarian and other cancers, currently in a Phase 1/2a study.READ MORE
Comments | 0 ADD COMMENT
World Congress on Advanced Biomaterials and Tissue Engineering
Jun 20 - Jun 21, 2018